Introduction {#s1}
============

Despite intensive effort in neuroscience research, very few new psychopharmacological agents have entered the market during recent decades. Antidepressants in general aim to increase monoaminergic neurotransmission by blocking monoamine reuptake, while antipsychotics mostly aim to reduce mesolimbic dopaminergic neurotransmission by blocking receptors including D~2~ and 5-HT~2A~ receptors ([@B1]). However, these effects are neither necessary nor sufficient for a favorable treatment response and the effectiveness of therapy is therefore suboptimal. Current selection of an appropriate antipsychotic or antidepressant drug to a great extent still relies on psychiatrists' clinical experience as well as on a potentially long trial and error approach, with potential serious adverse reactions such as suicidal ideation and behaviors. Moreover, while antidepressants and antipsychotics are superior compared to placebo ([@B2], [@B3]), their efficacy is not impressive keeping in mind the effect size of superiority over placebo ([@B4]). Since molecular targets for psychiatric drugs are not yet fully elucidated, many of the currently available drugs will likely remain the cornerstone of pharmacotherapy in psychiatry for the foreseeable future. It is therefore of paramount value to maximize their effectiveness prospectively by treatment personalization.

In general, differences between individuals in drug treatment response can be caused by environmental, physiological, and psychological factors, as well as by comorbidities and genetic variability ([@B5], [@B6]). With respect to the genetic component, one can estimate that roughly one quarter of the total variability in drug response is genetic in origin ([@B7]). To facilitate the transfer of genetic information to physicians, regulatory agencies incorporate pharmacogenomic drug labels into the summaries of product information (SmPC); here they specify which of the genetic variation information is important to consider with regard to drug prescription. Such drug labels include mandatory guidelines, recommendations and information about how pharmacogenomic variation should be taken into account regarding the indication or dosage - data that are expected to be beneficial for individualization of drug therapy ([@B6]). In addition two different organizations, CPIC (Clinical Pharmacogenetics Implementation Consortium) and DPWG (Dutch Pharmacogenetics Working Group) publish similar guidance based on their own expertise and judgment. It was published recently however, that the concordance among pharmacogenomic drug labels between FDA, EMA, DPGW, and CPIC is low and of drugs considered by all agencies; for only 18% of them is the information similar across the four agencies ([@B8]). For pharmacogenomic drug labels provided by the FDA and the EMA (or the Dutch or the German MPAs), the concordance is low ([@B8], [@B9]), in contrast to the high concordance between the FDA and the EMA regarding the approval of new drugs ([@B10]). Furthermore, the use of such labels in a clinical setting is relatively limited apart from in oncology ([@B11]).

There is substantial interindividual variability in the response and efficacy of CNS active drugs and it has become evident that genes encoding pharmacokinetic-related biomolecules have significant impact (<https://cpicpgx.org/guidelines/>). In particular, functional polymorphisms in genes encoding the drug metabolizing enzymes CYP2C19 and CYP2D6 are quite frequent among all populations ([@B12]) and these variants are associated with altered drug exposure sufficiently to support the clinical utility of *CYP2C19* and *CYP2D6* genotyping ([@B13]--[@B15]). In contrast, receptors that are currently used as drug targets for psychiatric drugs are evolutionary conserved to a higher extent than genes encoding drug metabolism and the actionability of pharmacodynamic-related genotyping is currently still questionable ([@B16]). However, when the functional interpretation of common or rare variants in such genes becomes available, it is clear that such pharmacogenomic information can be used to improve pharmacotherapy individualization ([@B17]).

Many findings to date in the field of pharmacogenomics in psychiatry have lacked consensus and yielded a lot of controversy. We herein review the most important studies in the field and summarize the current situation, outline future directions, and discuss possible implementation of genetic biomarkers in psychiatry with a particular focus on the *CYP2C19* and *CYP2D6* genes.

Biomarkers Based on Genes Coding Drug Metabolizing Enzymes {#s1_1}
----------------------------------------------------------

In phase I, drugs are usually transformed by oxidation, demethylation, reduction, or hydrolysis to more soluble compounds, which facilitates their subsequent elimination from the body. A major phase I enzyme family is the cytochrome P450s (CYPs), whose activity usually leads to the reduction of drug potency. The human liver possesses a wide spectrum of CYP isoforms; the most abundant isoforms (CYP1A2, CYP2C9, and CYP3A4/5) ([@B18]) account for more than half of total CYP content in the human liver and they participate in metabolism of roughly one third of psychiatric drugs ([@B19]). Importantly, certain drugs are known to induce or inhibit these enzymes and consequently, polypharmacy can affect the exposure of many psychiatric drugs (<https://drug-interactions.medicine.iu.edu/MainTable.aspx>). In addition, one recently published and adequately powered study suggests that the *CYP1A2* SNP rs2472297 may predict clozapine exposure ([@B20]) and potentially affect clozapine treatment. However, at this point, CYP2C19 and CYP2D6 enzymes seem to be more important for pharmacogenetics in psychiatry, since they contribute significantly to the phase I metabolism of more than two thirds of all currently available psychiatric drugs ([@B19]). Whilst CYP2C19 and CYP2D6 are much less abundantly expressed in the human liver than the other CYPs mentioned above, they seem to have a very high affinity for the molecular structures on which most of the currently available psychiatric drugs are based. However, unlike the major form of hepatic CYP3A P450 isoform CYP3A4 ([@B21]), the *CYP2D6* and *CYP2C19* genes are highly polymorphic, and this genetic variation is associated with profound changes in enzymatic capacity ([**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}). Owing to this genetic variability with demonstrated clinical relevance, all currently commercially available pharmacogenetic-based decision-support tools in psychiatry encompass the common variants in the *CYP2C19* and *CYP2D6* genes ([@B13]). However, in order to appropriately personalize treatment based on *CYP2C19/CYP2D6* genotype in psychiatry, prescribers need to know (i) how and in what depth *CYP2C19/CYP2D6* genotyping should be performed, (ii) the relationship between genotypic variation and the relevant linked phenotypes, and (iii) how to appropriately use this information to improve pharmacotherapy. While admirable progress in this regard has been made to date, certain research and clinical application gaps still remain to be addressed.

###### 

Relation between genotype and phenotype among diploid genotypes of CYP2C19 and CYP2D6.

  CYP2C19                                                                 
  ----------------------- ---------------------- ------------------------ --------------------
  Genotype                Functional Diplotype   Categorization           Enzymatic capacity
  *CYP2C19Null/Null*      PM/PM                  Poor                     0%
  *CYP2C19Null/Wt*        PM/NM                  Intermediate             50%
  *CYP2C19Null/\*17*      PM/UM                  Intermediate             60%
  *CYP2C19Wt/Wt*          NM/NM                  Normal                   100%
  *CYP2C19Wt/\*17*        NM/UM                  Ultrarapid               110%
  *CYP2C19\*17/\*17*      UM/UM                  Ultrarapid               120%
  **CYP2D6**                                                              
  Genotype                Functional Diplotype   Categorization           Enzymatic capacity
  *CYP2D6Null/Null*       PM/PM                  Poor                     0%
  *CYP2D6Null/\*41*       PM/IM                  Intermediate             5%
  *CYP2D6Null/\*9-10*     PM/IM                  Intermediate             15%
  *CYP2D6\*41/\*9-10*     IM/IM                  Intermediate OR Normal   20%
  *CYP2D6\*9-10/\*9-10*   IM/IM                  Intermediate OR Normal   30%
  *CYP2D6Wt/Null*         NM/PM                  Intermediate OR Normal   50%
  *CYP2D6Wt/\*41*         NM/IM                  Normal                   55%
  *CYP2D6Wt/\*9-10*       NM/IM                  Normal                   65%
  *CYP2D6Wt/Wt*           NM/NM                  Normal                   100%
  *CYP2D6WtX3*            UM/UM                  Ultrarapid               150%

NM, normal metabolizer; PM, poor metabolizer; IM, intermediate metabolizer; UM, ultrarapid metabolizer. The definition of the IM phenotype for CYP2D6 is different between sources. Enzymatic capacities are based on *in vivo* data from the recent three large-scale clinical studies ([@B14], [@B15], [@B22]). Enzymatic capacities may be substrate dependent.

###### 

world-wide frequencies of common variant *CYP2C19* and *CYP2D6* alleles.

  ---------------------------------------------------------------------------------
  Allele            Europeans   Africans   East-Asians   South-Asians   Americans
  ----------------- ----------- ---------- ------------- -------------- -----------
  *CYP2C19\*2*      **18.3**    **18.1**   **31.0**      **34.0**       **10.1**

  *CYP2C19\*3*      rare        rare       **6.7**       rare           rare

  *CYP2C19\*17*     **22.4**    **23.5**   1.5           **13.6**       **12.0**

  *CYP2D6xN*\       2.3         **9.3**    2             1.5            1
  *Amplification*                                                       

  *CYP2D6\*3*       4.1         rare       rare          rare           rare

  *CYP2D6\*4*       **15.5**    **11.9**   rare          **11.6**       **15.7**

  *CYP2D6\*5*\      3           4          **6.5**       2              3
  *Deletion*                                                            

  *CYP2D6\*6*       2.2         rare       rare          rare           rare

  *CYP2D6\*9*       1.6         rare       rare          rare           1.3

  *CYP2D6\*10*      rare        3.2        **58.7**      **6.5**        rare

  *CYP2D6\*17*      rare        **19.7**   rare          rare           1

  *CYP2D6\*29*      rare        **9.2**    rare          rare           rare

  *CYP2D6\*41*      3.0         3.0        3.0           **13.5**       3.5
  ---------------------------------------------------------------------------------

Frequencies are shown in percentages; the table is adapted from Zhou et al., 2017. Only variants with minor allelic frequencies (MAF) \> 1% in any of the populations are listed in this table. The MAF \< 1% variants are annotated as "rare," the 1% \< MAF \< 5% variants were represented with the MAF in percentages, and the variants with MAF \> 5% are represented with MAF in percentages and bolded.

CYP2C19 and CYP2D6 Functional Variant Genotyping {#s1_2}
------------------------------------------------

Functional *CYP2C19* and *CYP2D6* genetic variants include: (1) variants or Null alleles that encode nonfunctional proteins; (2) variants that cause a decrease in enzyme capacity or transcription levels compared to normal alleles, but not complete lack of enzyme; and (3) variants that result in an increase in enzyme capacity or transcription levels ([@B12]). Moreover, the *CYP2D6* gene belongs to one of the most complicated and polymorphic loci in the whole of the human genome ([@B23]). Deletion of the entire gene (*CYP2D6\*5*) and duplication/multiplication of the gene (e.g., *CYP2D6Wt*x2/N) occur frequently worldwide ([@B12]). For all genetic variants, a distinction between common (MAF \> 1%) and rare (MAF \< 1%) variants can be made. The frequencies of common *CYP2C19* and *CYP2D6* functional variant alleles worldwide, as previously described by ([@B12]), are listed in [**Table 1**](#T1){ref-type="table"}.

Currently, *CYP2C19*, *CYP2D6* and other CYP genotyping assays mostly cover only common variants, which is understandable from an economic point of view; however, there is an abundance of rare *CYP2C19* and *CYP2D6* variant alleles ([@B24]) (<https://www.pharmvar.org/gene/CYP2D6>). Thus, a substantial fraction of genetically caused variation in drug metabolism cannot be resolved unless extensive sequencing efforts are carried out in a psychiatric setting. The examination of big datasets from, for example, the EXAC consortium, reveals that among all mutations seen based on whole exome sequencing of \> 67,000 individuals, rare mutations account for over 90% of the number of unique SNVs and 50% of the SNVs identified are seen in only one individual ([@B24]). The total contribution of rare SNVs to interindividual variation in drug response is difficult to estimate but one quarter of the total variation appears to be a realistic figure ([@B25]). This means that in clinical practice, a substantial amount of the true functional genetic variation of drug metabolizing enzymes is not detected by using the commercially available genotyping tools. The importance of rare, often *de novo*, variants contribution for explaining interindividual variation in drug pharmacokinetics is also supported by results from twin studies where the differences in pharmacokinetics of e.g. torsemide and metoprolol were found to be much less between monozygotic as compared to dizygotic twins ([@B26]); only 30%--40% of the inheritable part of this variation was attributable to genetic variants known at that time. For more than half of the genes encoding drug metabolizing enzymes (other than *CYP2C19* and *CYP2D6*) and drug transporters, rare variants account for the entire genetic variability ([@B24]). Therefore, the only robust manner to determine the true genetic variation of patients in a comprehensive manner, would appear to be the use of sequencing techniques, which is not realistic in most of clinical facilities. However, it is likely that a transition to more use of these will appear in the coming years and that this will yield more optimal tools to assist treatment personalization in psychiatry.

Sequencing-based analyses present various challenges. Firstly, many pharmacogenes represent complex loci, including several genes and/or pseudogenes with very similar sequences. Conventional NGS analyses with short overlapping reads are unable to determine the genotype in such cases, as sequence similarities with neighboring genes/pseudogenes renders alignment of short sequences to the gene(s) in question very difficult or impossible. Long read sequencing or synthetic long read methods have to be employed for such loci ([@B27]). Secondly, NGS based sequencing is not able to make a firm assignment of the functionality of mutations identified, with respect to loss of function mutations and true synonymous mutations. However, relatively accurate algorithms to predict the functionality of mutations have been developed and trained on DME genes ([@B28]); the analysis workflow using such sequencing-based techniques is depicted in [**Figure 1**](#f1){ref-type="fig"}. In the future, the application of such a broad personalized approach for analyses of genetic variation could make pharmacogenomic predictions much more attainable for individual patients.

![Scheme for NGS-based sequencing for determination of global genomic variations of importance for preemptive pharmacogenetics advice. Common variants might also be directly detected by using standard genotyping techniques and conventional sequencing. The gene of interest might have its origin in a complex locus like the *CYP2D* locus and for proper sequencing e.g. long range PCR methods are necessary. From the (NGS, common known mutations will be evident but also rare mutations. These can be classified by subjecting the sequences to specific algorithms that can classify the mutations according to expected functional impact.](fpsyt-11-00094-g001){#f1}

Phenotypic Classification Based on *CYP2C19* and *CYP2D6* Genotype {#s1_3}
------------------------------------------------------------------

The cumulative allelic frequency of all *CYP2C19* and *CYP2D6* alleles that influence enzymatic capacity varies by ethnicity, but it is always substantial (higher than 50%); therefore, the total number of affected patients is considerable. Traditional classification usually divides patients into four groups: (**1**) poor metabolizers (PMs) are homozygous carriers of two loss-of-function alleles and their specific enzymatic capacity is completely abolished; (**2**) intermediate metabolizers (IMs) carry genotypes that are causing substantially reduced, but not absent, enzyme capacity; (**3**) normal metabolizers NMs homozygously carry normal (*Wt*) alleles and are associated with normal enzymatic capacity. NMs may also carry other genotypes as long as the enzymatic capacity is not significantly different compared with *Wt/Wt* carriers; (**4**) ultrarapid metabolizers (UM) carry genotypes linked to significantly increased enzymatic capacity compared with *Wt/Wt* carriers.

While this classification is informative and consistent with recent data, it is over-simplified, as certain genotypes that are classified within one category may carry different enzymatic capacities and the functional categorization of some specific genotypes is unclear ([**Table 1**](#T1){ref-type="table"}). A potential solution is the establishment of activity scores that may be used to translate highly complex *CYP2D6* or *CYP2C19* diplotype data into one value, which can be used as the estimate for phenotypic alteration ([@B29]). However, the precision of such an activity score index would require very reliable estimates of how much each variant allele affects enzymatic capacity and the activity score may also be substrate dependent. Consequently, such a classification is very simple for *Null* alleles since they completely abolish enzymatic capacity (0% activity score compared with Wt allele), but quite complicated for the other functional alleles. According to our data from 2,087 CYP2C19 genotyped patients treated with escitalopram, the *CYP2C19\*17* allele increases the enzymatic capacity of CYP2C19 by only approximately 20% compared with *CYP2C19Wt* ([@B15]). Similarly, in our data from 1,003 *CYP2D6* genotyped patients treated with venlafaxine, the *CYP2D6\*41* allele reduces the enzymatic capacity of CYP2D6 by approximately 85% compared to *CYP2D6Wt*, while *CYP2D6\*9* and *CYP2D6\*10* alleles reduce CYP2D6 enzymatic capacity by approximately 70% compared to *CYP2D6Wt* ([@B22]). [**Table 2**](#T2){ref-type="table"} illustrates the metabolizer categorization and activity scores based on *CYP2C19* and *CYP2D6* genotypes; however, although these estimates are quite reasonable, the activity scores may also be drug- and ethnicity-dependent and more *in vivo* studies are needed to improve the trustworthiness of the activity scores.

While associations between functional diplotype category and expected enzymatic capacity are informative, the clinically relevant information is how *CYP2C19* and *CYP2D6* genotypes translate into phenotypes such as drug concentration, and whether genotypes are associated with differential treatment outcomes. It is expected that the occurrence of *CYP2C19* and *CYP2D6* variant alleles will affect the exposure of drugs metabolized by CYP2C19 and CYP2D6, and conversely, that drugs which are specifically metabolized by CYP2C19 or CYP2D6 will be mostly affected in terms of relevant clinical phenotypes. However, specific associations and the magnitudes of such effects have to be established and quantified accordingly.

Escitalopram and sertraline are examples of drugs that are metabolized predominantly by CYP2C19 and as expected, a profound increase in escitalopram and sertraline exposure is observed in CYP2C19 PMs ([@B15], [@B30]). Escitalopram treated PMs are more prone to side effects and treatment dropout ([@B15], [@B31]); however, they also respond better to escitalopram if treatment is tolerated ([@B31], [@B32]). The increase in enzymatic capacity caused by the *CYP2C19\*17* variant seems to also affect escitalopram treatment outcome, likely by reducing the exposure ([@B15], [@B33]). Patients carrying *CYP2C19\*1/\*17* and *CYP2C19\*17/\*17* genotype had a 50% increase in treatment failure rate compared with NMs ([@B15]). Moreover, replicated findings that CYP2C19 UMs treated with escitalopram exhibit increased suicidal ideation ([@B34], [@B35]) indicates that distinguishing between CYP2C19 NMs and UMs is clinically relevant for the escitalopram treatment.

Risperidone is an example of a drug that is metabolized predominantly by CYP2D6, and in a study of 1,288 patients, approximately 1.4- and 1.6-fold risperidone exposure increase was observed in IMs and PMs, respectively ([@B14]). Since the therapeutic window for risperidone is quite narrow, this exposure increase is likely the reason behind the higher incidence of risperidone-associated adverse drug reactions ([@B36]) and treatment failure ([@B14]) observed among PMs compared with NMs. Furthermore, an increased treatment failure rate is also observed in Ums ([@B14]), indicating that they might be exposed to insufficient drug levels. Many other antipsychotics, such as aripiprazole and haloperidol, are metabolized by CYP2D6. Although aripiprazole metabolism is not as CYP2D6 selective as that of risperidone, CYP2D6 genotype clearly affects drug exposure for aripiprazole: a 1.6-fold increased drug exposure is observed in CYP2D6 PMs in a study of 1,334 patients ([@B14]). Since aripiprazole has a very long half-life (almost a week), the net clinical effect is significant; hence, halving the aripiprazole dose is recommended on the FDA drug label for known CYP2D6 PMs (FDA Aripiprazole).

Translation of CYP2C19 and CYP2D6 Phenotypes Into Clinical Recommendations {#s1_4}
--------------------------------------------------------------------------

It is not realistic to expect that clinicians are able to follow scientific literature on a regular basis in addition to their clinical work, and it is therefore essential to differentiate robust scientific evidence from the findings that need further validation and to translate the former into informative treatment guidelines. There is a research gap in knowledge regarding the cost-effectiveness of preemptive genotyping in psychiatry; however, it has previously been suggested that pharmacogenetic testing in psychiatry might be cost-effective if the tests became cheaper. Importantly, most of the models did not consider indirect costs, which are known to be high for psychiatric patients ([@B37]--[@B39]). In the EU, the direct and indirect costs of mental health disorders have been estimated at €798 billion and are expected to double by 2030 ([@B40]). The cost of genetic testing is dropping each year, rendering its implementation in daily psychiatric care more and more possible.

In addition, utilization of the outputs from pharmacogenetic testing can be very challenging in the complex real-life situations ([@B41]). Patients often suffer from multiple disorders and are therefore taking combinations of medications, which can influence the metabolism of the CNS active drugs. This phenomenon causes the conversion of genetic EMs into phenotypic UMs, IMs, or PMs (phenoconversion) owing to the effects of concomitant medications on enzyme inhibition and induction and this can modify clinical response to drugs. This has mostly not been taken into account in clinical studies and there is a therefore a real risk that such studies may have missed clinically relevant phenomena.

Although the scientific evidence for the above mentioned *CYP2C19* and *CYP2D6* genes is strong enough to recommend clinical application, larger international and nonindustry-funded implementation studies demonstrating feasibility and cost-effectiveness in real-world settings are lacking. Real-world settings include people that use more than one drug, which is something that the current guidelines do not yet cover. Possible obstacles in terms of feasibility include the availability of an efficient system to generate, deliver and implement genotyping in the clinical prescription of psychiatric medication. At this time, despite gene-dosing advice for many antidepressants ([**Tables 3**](#T3){ref-type="table"} and [**4**](#T4){ref-type="table"}) and antipsychotics ([**Table 5**](#T5){ref-type="table"}) these are all prescribed to patients with almost no preemptive genotyping or genetic analyses during treatment, not even when side effects occur or when the pharmacotherapy is inefficacious.

###### 

Dosing advice of antidepressants based on CYP2C19 and CYP2D6 phenotype according to DPWG and/orCPIC; see ([@B77]).

  SSRI/SNRI      Poor metabolizer                      CYP2C19                     CYP2D6                                                                                                                                        
  -------------- ------------------------------------- --------------------------- --------------------------- --------------------------- ---------------------------- ---------------------------- --------------------------- --------------------------------------------------
  Citalopram     50% of starting dose or alternative   Recommended starting dose   Recommended starting dose   Alternative drug            Recommended starting dose    Recommended starting dose    Recommended starting dose   Recommended starting dose
  Escitalopram   50% of starting dose or alternative   Recommended starting dose   Recommended starting dose   Alternative drug            Recommended starting dose    Recommended starting dose    Recommended starting dose   Recommended starting dose
  Fluvoxamine    Recommended starting dose             Recommended starting dose   Recommended starting dose   Recommended starting dose   25%--50% or alternative      Recommended starting dose    Recommended starting dose   
  Mirtazapine    Recommended starting dose             Recommended starting dose   Recommended starting dose   Recommended starting dose                                                                                         
  Paroxetine     Recommended starting dose             Recommended starting dose   Recommended starting dose   Recommended starting dose   Alternative or 50%           Recommneded starting dose    Recommended starting dose   Recommended starting dose
  Sertraline     50% of starting dose                  Recommended starting dose   Recommended starting dose   Recommneded starting dose                                                                                         
  Venlafaxine                                                                                                                              Alternative drug or adjust   Alternative drug or adjust   Recommended starting dose   Likely higher dose e.g. 150% or alternative drug

###### 

Tricyclic antidepressants dosing advice based on CYP2C19 and CYP2D6 phenotype according to DPWG and/or CPIC; see ([@B78]).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **TCAs**        CYP2C19                              CYP2D6                                                                                                                                                                                
  --------------- ------------------------------------ --------------------------- --------------------------- ----------------------------------- ------------------------------ ------------------------------ --------------------------- -----------------------------
  Amitriptyline   Nortriptyline/\                      Recommended starting dose   Recommended starting dose   Nortriptyline/\                     No TCA or 50%                  Reduce dose by 25%             Recommended starting dose   No TCA or higher dose
                  desimpramine or 50% dose reduction                                                           desimpramine or 50% dose increase                                                                                             

  Clomipramine    Nortriptyline/\                      Recommended starting dose   Recommended starting dose   Nortriptyline/\                     No TCA or 50% dose reduction   Reduce dose by 25%             Recommended starting dose   No TCA or higher dose
                  desimpramine or 50%                                                                          desimpramine or 50% dose increase                                                                                             

  Doxepine        Nortriptyline/\                      Recommended starting dose   Recommended starting dose   Nortriptyline/\                     Reduce dose by 60%             Reduce dose by 20%             Recommended starting dose   No TCA or 100% higher dose
                  desimpramine or 50%                                                                          desimpramine or 50%                                                                                                           

  Imipramine      Nortriptyline/\                      Recommended starting dose   Recommended starting dose   Nortriptyline/\                     No TCA or 70% dose reduction   No TCA or 30% dose reduction   Recommended starting dose   No TCA or 70% dose increase
                  desimpramine or 50%                                                                          desimpramine or 50%                                                                                                           

  Nortriptyline                                        Recommended starting dose   Recommended starting dose   100%                                No TCA or 60% dose reduction   No TCA or 40% dose reduction   Recommended starting dose   No TCA or 60% dose increase
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Antipsychotic dosing advice based on CYP2D6 phenotype according to DPWG (<https://www.pharmgkb.org/gene/PA128/guidelineAnnotation/PA166104988>) according to the recent large-scale study results ([@B14]).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                   CYP2D6                                                                                                                              
  ---------------- --------------------------------------------------- --------------------------------------------------- --------------------------- ---------------------------------------------------
  Aripiprazole     Reduce maximum dose by 33% (to 20 mg/day)           Reduce maximum dose by 33% (to 20 mg/day)           Recommended starting dose   Be alert for subtherapeutic drug levels (TDM) OR\
                                                                                                                                                       Select alternative drug

  Risperidone      Reduce maximum dose by 33% (to 4 mg/day)            Reduce maximum dose by 33% (to 4 mg/day)            Recommended starting dose   Be alert for subtherapeutic drug levels (TDM) OR\
                                                                                                                                                       Select alternative drug

  Haloperidol      Reduce the dose by 50% OR select alternative drug   Be alert to ADRs OR select alternative drug         Recommended starting dose   Be alert for subtherapeutic drug levels (TDM) OR\
                                                                                                                                                       Select alternative drug

  Zuclopenthixol   Reduce the dose by 50% OR select alternative drug   Reduce the dose by 25% OR select alternative drug   Recommended starting dose   Be alert for subtherapeutic drug levels (TDM) OR\
                                                                                                                                                       Select alternative drug
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Pharmacodynamic Pharmacogenetics {#s1_5}
--------------------------------

Research oriented towards pharmacodynamic-related biomarkers has to date mainly focused on functional variants of genes encoding drug targets for currently available antipsychotics and antidepressants such as SERT (*SLC6A4*), NET (*SLC6A2*), *DRD2*, *HTR1A*, and *HTR2A*. In addition, genes coding pivotal proteins involved in neuroprotection, stress-response and immune system activation such as BDNF, FKPB5, CHRBP, HLA-A, and HLA-B have been considered. However, despite initial enthusiasm, most of these polymorphisms have not yet been validated for clinical utility.

One example is a polymorphism in the promoter region of the serotonin transporter (*5-HTTLPR*), which is one of the most studied genetic polymorphisms for response to antidepressants. The deletion of a 44-bp long region gives rise to a short (S)/long (L) variant in the promoter region, the short having been associated with lower levels of SERT expression ([@B42]). The long (L) variant was initially associated with better response to SSRIs ([@B43]). After 28 studies were conducted to either validate or dismiss this finding, a recent systematic review was performed and according to the meta-analysis therein, this variant did not conclusively affect SSRI treatment outcome ([@B44]). Although it may nonetheless be possible that it is relevant together with other data([@B45]), at the present date, it is unlikely that *5-HTTLPR* genotyping, which is present in more than one third of currently available commercially assays ([@B13]) can be utilized as an effective clinical predictor for drug response. Similarly, rs7997072 (*HTR2A*) ([@B46]), rs5569 (SLC6A2) ([@B47]), and rs1360780 (FKBP5) ([@B48]) were suggested to be predictors of response to SSRIs, SNRIs, and all antidepressants admixed respectively with reasonable confidence levels and effect sizes. However, these findings were not replicated in a precise manner by the GENDEP study ([@B49]). For example, for the *HTR2A*, different markers (rs2224721 and rs9316233) in the same region of the gene (intron 2) as rs7997072 were nominally significantly associated with response to escitalopram in GENDEP study ([@B49]). It is likely that the effect of *HTR2A* polymorphism involves complex polygenic gene-environment interactions; however, these interactions are yet to be elucidated. A further example is the -141C Ins/Del polymorphism in the *DRD2* gene, which in a GWAS was associated with risk of schizophrenia and was suggested to predict response to antipsychotic therapy ([@B50]); in addition, a recent report linked the minor allele with less favorable response to clozapine ([@B51]). However, the level of significance was only marginal (*p* value between 0.05 and 0.01), suggesting that the clinical relevance of this SNP, when considered alone, is limited. Of note, CYP2C19 and CYP2D6 are both expressed in the human brain ([@B52], [@B53]), where they can metabolize trace amines to monoamines and affect psychiatric-relevant phenotypes and pharmacological treatment outcomes ([@B54], [@B55]). Substantial effort has been made to elucidate the endogenous role of these two enzymes in the brain and the impact of variant *CYP2C19* and *CYP2D6* alleles. However, it is not yet clear whether their endogenous role and local drug metabolism can affect treatment with psychiatric drugs. This topic however, is beyond the scope of this review; for further reading see ([@B56]) and. P-glycoprotein (P-gp) is a plasma membrane efflux pump encoded by the *ABCB1* gene which acts as a drug transport mechanism, actively exporting drugs from cerebrospinal fluid to blood. Many psychiatric drugs are substrates for P-gp and functional polymorphism in *ABCB1* might hypothetically change the levels of such drugs at the site of action; however, although certain variants of *ABCB1* have been associated with alterations in drug disposition and response, the results have been highly conflicting, with questionable clinical relevance ([@B57]).

Other types of polymorphic loci, such as the HLA locus, can be used for prediction of drug response and adverse drug reactions. For example, the *HLA-B\*1502* allele is connected with an increased risk of developing Stevens-Johnson syndrome (SJS) and its related disease, toxic epidermal necrolysis (TEN) during carbamazepine or oxcarbazepine treatment ([@B58]). *HLA-B\*1502* is common among East Asians (6.9%, apart from Japanese at \<1% and Korean at \<2.5%); Oceanic (5.4%); and South/Central Asian (4.6%) ethnic groups have relatively high frequencies of *HLA-B\*1502* ([@B58]). Among carbamazepine treated patients, *HLA-B\*1502* increases the risk of SJS/TEN hundredfold (OR: 113.4; 95% CI: 51.2-251.0) ([@B59]). While the positive predictive value of *HLA-B\*1502* genotype is much less for oxcarbazepine then for carbamazepine, the negative predictive value for both is nearly 100% in South East Asian populations ([@B60]). In a trial of 4,877 patients in Taiwan, *HLA-B\*1502* genotyping completely prevented SJS/TEN from occurring, while the estimated historical incidence of carbamazepine-induced SJS-TEN (0.23%) would translate into approximately 10 cases among study subjects ([@B61]). As a result of this evidence, the FDA introduced a black-box warning on the carbamazepine drug label and proscribed mandatory genotyping for the *HLA-B\*1502* in patients with documented Asian origin (<https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016608s101,018281s048lbl.pdf>). CPIC provides guidelines for *HLA-B\*1502* and *HLA-A\*31:01* variants for all carbamazepine and oxcarbazepine-treated patients, irrespective of region of origin or ethnic group ([@B58]). This example illustrates how drug labelling and clinical guidelines follow, once the clinical studies are able to provide firm and robust evidence about the usefulness of preemptive genotyping.

In the present situation, where commercial companies specialized in the sale of genetic test results for profit have proliferated, there is an increasing risk of advertisements relatied to offering nonvalidated pharmacodynamic- and pharmacokinetic-based genotypes directly to consumers (patients). In fact, for inadequately informed clinicians, such genetic testing may actually cause more harm than benefit. One of the examples that illustrates this possibility is a recently published case report describing a patient whose family and outpatient care provider received the information that he was a -141Cdel carrier. Since the genetic test results implied that the patient was expected to poorly respond to clozapine, objection was raised when switching the antipsychotic to clozapine was suggested to the patient. However, since the symptom level was severe, after consulting with the hospital medical director, clozapine was nonetheless administered to the patient and this had a remarkably good and rapid effect ([@B62]). As previously mentioned, the *DRD2* -141C ins/del is very far from a validated biomarker for clozapine response and is seldom present on any of the commercially available assays ([@B13]). This case therefore illustrates the danger of testing using insufficiently validated genetic markers and provides an example of how such testing can cause a setback in the clinician-patient relationship. We therefore conclude that healthcare providers who order and deal with pharmacogenetic testing should have a moral and legal responsibility to educate themselves and their patients about pharmacogenetic testing and its limitations. Furthermore, regulatory and legislative frameworks should be developed and implemented to guide this process.

Discussion {#s2}
==========

The number of drugs carrying pharmacogenomic labels continues to increase ([@B6], [@B63]), while in contrast, the chance of discovering more blockbuster drugs is decreasing. Therefore the advancement of pharmacotherapy in psychiatry and in general in the forseeable future will likely be dependent on adequate drug treatment personalization ([@B64]). One example is the treatment of cystic fibrosis, where genotyping of the *CFTR* gene directly impacts the likelihood for successful treatment using *CFTR* modulators ([@B65]). Guidelines for pharmacogenomic work during drug development have been developed and are instrumental tools for the pharmaceutical industry (<https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacogenomic-practice-first-version_en.pdf>), particuarly in oncology.

With respect to psychiatry, the HLA markers described above are relevant for mood stabilizers carbamazepine and oxcarbamazepine. While genotyping to avoid life-threatening adverse drug reactions is mandatory for the HLA markers, pharmacoeconomic analyses provide support for the cost-effectiveness of other pharmacogenetic-based treatment decisions, especially in the case of *CYP2D6* ([@B66], [@B67]). Currently, it seems evident that, out of many proposed markers, only genetic variants located in the *CYP2C19* and *CYP2D6* genes are of value for optimizing antipsychotic and antidepressant drug treatment. These genes were consistently found to influence pharmacotherapy response in seven randomized controlled trials when genotyping was performed prospectively ([@B68]--[@B74]). While genotyping pharmacodynamic genes such as *DRD2* is not at this time sufficiently supported by research results, it is possible that machine learning of multivariate data including pharmacokinetic and pharmacodynamic genes may produce associations of interest.

Variants in pharmacogenes often have low allele frequencies and thus for good power, thousands of patients, or meta-analyses in which variants are grouped together into functional categories, are required for robust results. While neuropsychopharmacogenomic clinical trials including a health economic component could strengthen the evidence for cost savings, in general there is a need for a larger, nonindustry sponsored prospective trials. For some gene-drug pairs, some might argue that the strength of the evidence is sufficient and that such a clinical trial might be unnecessary and unethical. For most of the drugs however, the situation is not quite clear and further large analyses are indicated; moreover, even for the validated drug-gene pairs, some would argue that clinical evidence are still incomplete ([@B16]). It is also possible that further retrospective analyses of relevant clinical trials already conducted, especially where cost-related data are available, could generate informative health economic data. Certainly, pharmacogenomic analyses should incorporate comprehensive genomic analysis (sequencing) and also carefully consider factors that may influence the findings, such as comedications and pathophysiolgical factors.

Therapeutic drug monitoring (TDM) of drug plasma levels has been used in psychiatry for a long time, in particular for tricyclic antidepressants, lithium, and clozapine. TDM captures all factors of interindividual variability in drug metabolism, while genotyping can offer only a solid prediction of patient metabolic capacity ([@B19]); however, genotyping is possible before drug treatment is initiated, whereas TDM can only be performed when the drug levels reach steady-state and when the patient is possibly already exposed to adverse drug reactions. Therefore, in an ideal constellation, a psychiatrist would take into consideration all available genetic, somatic, dietary and environmental parameters to make the best possible drug and dose selection at initiation of therapy for each individual patient, and once the drug levels reach steady-state, TDM would be utilized to ascertain whether such an educated decision was indeed optimal. Since the efficacy rate is only 30%--40% for antidepressants and antipsychotics ([@B75], [@B76]) despite TDM, there is clearly room for an improvement in approach.

Conclusion {#s3}
==========

To conclude, there are good pharmacogenetic clinical recommendations for a wide selection of psychopharmacological agents based on *CYP2C19* and *CYP2D6* functional diplotypes. In addition, recent adequately-powered studies (n \> 1,000) have yielded more clinically useful information and support the clinical utility of preemptive pharmacogenomics for specific gene-drug pairs. To extend the knowledge beyond these gene-drug pairs, further large-scale prospective randomized trials having a sequencing-based genetic approach and/or reanalyses of studies with economic data are needed. At this point, there would appear to be sufficient data to support implementation of pharmacogenomics in to daily psychiatric practice in patients experiencing side effects and/or inefficacy ([**Tables 1**](#T1){ref-type="table"}--[**3**](#T3){ref-type="table"}). Finally, it is crucial that clinicians are adequately educated in the field of pharmacogenetics and equipped with adequate guidelines and decision support tools to interpret genotyping results and translate them into the clinical setting.
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